Innovation in pharma today means faster ‘time to insight’. However, trying to innovate with disconnected, fragmented data is slow, costly and frustrating—for both pharma companies and patients. In this paper, we explore the potential of a world where data is freed from silos. We examine in more detail the factors that are preventing this and what it will take to collapse prohibitive structures with appropriate technologies, processes and approaches.